About CIPM

CIPM is a leading center in innovative research for personalized medicine since its establishment in 2012 at KAU. Thanks to the dynamic leadership and team of devoted researchers, today Next Generation Sequencing based panels and PGD/PGS remain its hallmarks. As the center progresses towards KSA Vision 2020 and subsequently Vision 2030, a new era of dynamic translational research has led to the establishment of a niche in “Innovative Precision Therapeutics” (IPT). With stringent management plan and interdisciplinary / intra-institutional approach and in coordination with ministry of education RDO; IPT at CIPM is determined to have a comprehensive impact all the way from grass root reforms to global recognition.   

The sequencing of the human genome has shown that there is no single generic clinical management protocol for any disease. The genetic and epigenetic composition of each person is going to affect his or her likelihood of developing a disease, having this disease diagnosed and alter his or her response to treatment.
In addition, it is plausible to assume that wrong diagnoses are made because a particular patient is from an ethnic group which has not been studied extensively and the lack of information about the genetic modifiers of diseases in that group limited the ability to provide an accurate risk assessment and direct the clinician to use the right diagnostic tools.

The cases of the anti-coagulant drug, Warfarin, and Herceptin, the antibody-based treatment of breast cancer are the best example known so far for how our genetic makeup can affect our response to treatments.

The Solution is Personalized Medicine

Personalized medicine is about delivering tailor-made medical treatments specific for every patient’s needs.
In addition to the traditional clinical parameters collected about a patient (age, sex, dietary habits, family history of disease, environment, etc.), information about the patient’s genotype epigenotype gene expression profile could be utilized to provide a better fitting treatment regime.Such information could be used in disease stratification and choosing the right medication (or combinations) as well as the right dose.

This will help provide an innovative and individualized therapeutic approach for an individual's disease, or initiate a preventative measure that is particularly suited to that patient at the time of administration. Although screening patients for single-gene mutations is regarded beneficial and is being widely used in the diagnosis and prognosis of diseases, but the fraction of patients who benefit from such approaches remain insignificant. Consequently, global approaches such as the whole-genome sequencing or other tools that provide comprehensive picture of the patients’ genomes are essential. This is possible only under the umbrella of a committed research team with an interdisciplinary approach at addressing the problems that are common in the Kingdom of Saudi Arabia.

The establishment of KACST TIC in Personalized Medicine (CIPM) and the promotion of the “Personalized Medicine” concept will have wider implications in the health sector, including hospital laboratory diagnostic units as well as the higher education sector. We strongly believe that the national planning sector will also benefit as personalized medicine will offer more efficient treatments and subsequently will result in less people suffering ill health taking them back to the job market. Furthermore, potential positive impacts will be manifested by overall reduced expenditure on provision of health care as inaccurate diagnosis will be eliminated and therapeutic regimens will become more efficient. This will lead to reduced hospital bed-blocking and reduced wastage on expensive drugs that may have been used needlessly. In addition, the center will enhance the research infrastructure by providing expertise, tools and equipments to carryout cutting edge research. Such advanced infrastructure in a university setting is bound to attract the attention of the students and enrich their imagination and foster the research and development culture.

This report details progress achieved in the period between October 2012-March 2013. In summary, the CIPM position within the King Abdulaziz University (KAU) organizational structure is now determined. The CIPM organizational structure has been determined, closely following the original proposal. The research themes and thrusts are in place for the next two years, with one project already completed. A bermanent base for CIPM operations is being readied at the King Fahd Medical Research Center (KFMRC) at KAU. Laboratory space and access to KAU core services guarantees excellent environement for conducting cutting-edge research. Finally, we hope to show in this report the clarity of our vision and the consistency in our approach and hope that KACST will continue to support us with the allocated TIC budget.

Contact Us

King Fahd Medical Research Center, King Abdulaziz University

(966) 12-695-2000, Ext: 72143


Last Update
8/29/2021 1:56:29 PM